文献速递造血干细胞移植与细胞治疗

集中监管体系下的分散治理区域授权促进中国细胞治疗发展

Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China.
PubMed 文献 · Lancet Haematol · 2022-01-01

本文回顾中国细胞治疗监管改革历程,指出2017年以来灵活监管框架推动细胞治疗发展并使中国重回该领域前沿,但商业化产品的监管、治理和管理仍面临挑战。文章呼吁建立清晰连贯的立法体系以促进细胞治疗的创新与产业化。

要点

  • 中国科学家1991年开展血友病B基因治疗临床试验,2003年中国成为首个批准商业基因治疗产品的国家。
  • 2017年以来灵活的监管框架促进了细胞治疗发展,使中国重回该领域全球前沿。
  • 商业化细胞治疗产品的监管、治理和管理仍面临挑战,需建立清晰连贯的立法体系。

核心结论

  • 2017年以来灵活的监管框架促进了中国细胞治疗发展,使中国重回该领域全球前沿,但商业化产品的监管、治理和管理仍面临挑战。
  • 需要进一步努力建立具有清晰连贯政策的立法体系,以支持中国日益增多的细胞治疗应用,实现更有规范性、更勤勉和更知情的流程。

研究设计与样本

  • 本文为系列综述文章,从历史视角概述中国临床细胞治疗当前的监管改革,并强调可促进中国细胞治疗创新与产业化的重要因素。

主要发现

  • 中国科学家于1991年开展了针对血友病B患者的第二项基因治疗临床试验,中国于2003年成为首个批准商业基因治疗产品的国家。
  • 由于早期缺乏清晰连贯的细胞治疗政策等原因,中国几乎失去了在该领域的领先地位。
  • 2017年以来灵活的监管框架促进了细胞治疗发展,取得了显著进展,使中国重回该领域全球前沿。
  • 中国政府2019年推出的一些细胞治疗政策促进了中国细胞治疗的增长,但商业化产品的监管、治理和管理仍面临挑战。

局限性

  • 原文指出商业化细胞治疗产品的监管、治理和管理仍面临挑战。
  • 原文结论指出需要进一步努力建立具有清晰连贯政策的立法体系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy is an example of gene engineering-based cellular therapy, which combines immunotherapy, gene therapy, and cellular therapy. Historically, the second clinical trial of gene therapy for patients with haemophilia B was conducted by Chinese scientists in 1991, and China became the first country to approve a commercial gene therapy product in 2003. However, China almost lost its lead in this field, partly due to an early scarcity of clear and cohesive policies regarding cellular therapy. Cellular therapy is not only a novel medical practice but also a medicinal product. The increasing commercialisation of globally approved cell therapy products made the Chinese Government issue a series of relevant policies to promote the canonical development of cell therapy and its standardisation in China. Encouraged by flexible regulatory frameworks that have facilitated the development of cellular therapy since 2017, remarkable progress has been achieved, thereby putting China back at the forefront of the field worldwide. Some policies on cellular therapy launched by the Chinese government in 2019 have contributed to the growth of cellular therapy in China; however, the regulation, governance, and management of commercialised products remain challenging. This Series paper aims to provide an overview of the current regulatory reforms on clinical cellular therapy in China with a historical perspective. We also highlight several important contributors that could promote innovation and industrialisation of cellular therapy in China. Further efforts are needed to establish a legislative system with clear and cohesive policies for the increasing use of cellular therapy in China, enabling a more prescriptive, diligent, and informed process.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Li X, Dai H, Wang Y, et al. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China. Lancet Haematol. 2022. PMID: 36455609. doi:10.1016/S2352-3026(22)00331-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。